Hangzhou AllTest Biotech Co., Ltd is located in 550#，Yinhai Street, Baiyang District, Hangzhou Economic-Technological Development Area, the company registered capital of 15 million RMB. The company’s total construction area is about 3200 M2. The company holds strong ability of scientific research and innovative technology. AllTest Biotech leads the development frontier of biological technologies such as monoclonal antibody-colloidal gold and latex technique, gene engineering, compound antigen and immunoassay.
AllTest Biotech is thriving on design, development, manufacturing and sales of the lateral flow rapid IVD products and food safety test product. The product is broadly recognized in the international market for its rapid, convenience and accurateness. AllTest Biotech will strive to become the leader and pioneer in the diagnostic industry field of China and the world.
Abnova is the first biotech company successfully integrated the IT-style management and industrial-scale antibody manufacturing. Our goal is to have at least one antibody to every human expressed gene in human genome.
In Phase I of our business plans, we vastly expand the scope and availability of antibody reagents for the research market by taking a genome-wide approach to the high throughput production of human protein and antibody. There products are marketed through a combination of E-commerce based direct sales and a multi-tiered, sales network of over 49 distributors around the world.
Starting from Year 2009 to 2013, in Phase II of the business plans, we have diversified into the systems arena focusing on antibody pairs, ELISA kits and instrumentation for rare cell isolation. In Phase III, we focus on in vitro diagnostics development concentrating on non-invasive, liquid biopsies of circulating tumor cells, ctDNA, and exosomes for precision medicine. Now in Phase IV (Year 2017 and later), we have focused on drug development specializing on immunotherapy. The value-added business has set the path of company's future growth and provided opportunity for Abnova to contribute to the biotech industry at large.
We welcome researchers, biotech, and pharmaceutical companies to work with us and succeed together!
ImmunoDiagnostics Limited (IMD) is a spin-off biotech company from The University of Hong Kong. The company is dedicated to biomarker discovery, assay development and in vitro diagnostics (IVD) of major chronic diseases, particularly on cardio-metabolic diseases and autoimmune diseases.
The company has established an integrated “biomarker/antigen-antibody-immunoassay” pipeline for the development of innovative diagnostic products. Firstly, new biomarkers are expressed in the form of recombinant proteins with different protein expression systems and are subsequently purified to a final purity of above 95% by procedures such as affinity purification, ion-exchange chromatography, size exclusion chromatography and gel infiltration. Secondly, by using high-quality recombinant proteins as antigens, antibodies are generated in the serum of host animals such as rabbits or mice after immunization and are further purified from the serum by performing both IgG- and antigen-based affinity purification; Lastly, highly specific antibodies are used for the development of a series of innovative semi- or fully automatic immunoassays with supreme sensitivity, specificity and efficiency, including immunoblotting assays, enzyme-linked immunosorbent assays (ELISAs), as well as immunoturbidimetry assays (ITAs), chemiluminescence assays (CLIAs), which can be directly applied in clinical diagnosis.
KYinno is dedicated to oncology drug discovery service and customized product development, with a focus on immuno-oncology and next-generation kinase inhibitor discovery.
Our service platforms include:
- Engineered custom cell line development
- Cell-based assay validation and compound screening
- Phage display library and hybridoma technology for antibody drug discovery
- Cancer cell panel compound profiling and biomarker discovery
Our products include:
- Engineered reporter cell lines
- Antibody and proteins with fully validated functions in reporter cell lines
Our team members have years of experience in the pharmaceutical and biotechnology industry in both China and U.S.
PharmAbcine Inc. is a bio venture specialized in R&D of antibody treatment in the clinical stage and currently possesses core technologies
such as potent antibody development technology using potent non-immune scFv phage display library, new-generation double target antibody
production technology, and antibody production technology using cancer stem cell library.
Since we were established in 2008 we have been devoted to developing new cancer antibody drugs and laying a foundation for TTAC-0001 and PMC-001.
We will constantly develop pipelines for sustainable growth with a vision to release a new global blockbuster bio drug by 2020 and become a global bioengineering company.